Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Summary

The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Timeline

Start

2018-05-08

Primary completion

2020-07-08

Completion

2020-07-08

Outcome

Met primary endpoint

release “SKYRIZI ™ met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx ® in a head-to-head Phase 3 study.” abbvie.com ↗

Publications

• Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575. doi: 10.1007/s13555-021-00679-6. Epub 2022 Jan 20.

Drugs

Indications